This is a preview of subscription content, log in via an institution to check access.
Notes
2014 euros
National Institute for Health and Care Excellence (UK WTP threshold valued British pounds)
Reference
van Asten F, et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration - A cost-effectiveness analysis from a societal perspective. PLOS One : 17 May 2018. Available from: URL: https://doi.org/10.1371/journal.pone.0197670
Rights and permissions
About this article
Cite this article
Bevacizumab most cost-effective treatment for AMD. PharmacoEcon Outcomes News 804, 6 (2018). https://doi.org/10.1007/s40274-018-4970-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-018-4970-7